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Abstract: Arenicin-1, a β-sheet antimicrobial peptide isolated from the marine polychaeta Arenicola
marina coelomocytes, has a potent, broad-spectrum microbicidal activity and also shows significant
toxicity towards mammalian cells. Several variants were rationally designed to elucidate the role of
structural features such as cyclization, a certain symmetry of the residue arrangement, or the presence
of specific residues in the sequence, in its membranolytic activity and the consequent effect on
microbicidal efficacy and toxicity. The effect of variations on the structure was probed using molecular
dynamics simulations, which indicated a significant stability of theβ-hairpin scaffold and showed that
modifying residue symmetry and β-strand arrangement affected both the twist and the kink present
in the native structure. In vitro assays against a panel of Gram-negative and Gram-positive bacteria,
including drug-resistant clinical isolates, showed that inversion of the residue arrangement improved
the activity against Gram-negative strains but decreased it towards Gram-positive ones. Variants
with increased symmetry were somewhat less active, whereas both backbone-cyclized and linear
versions of the peptides, as well as variants with R→K and W→F replacement, showed antimicrobial
activity comparable with that of the native peptide. All these variants permeabilized both the outer
and the inner membranes of Escherichia coli, suggesting that a membranolytic mechanism of action
was maintained. Our results indicate that the arenicin scaffold can support a considerable degree
of variation while maintaining useful biological properties and can thus serve as a template for the
elaboration of novel anti-infective agents.
Keywords: marine peptides; arenicin-1; molecular symmetry; structure–activity relationship;
antibacterial; cytotoxic; chemical synthesis; molecular dynamics
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1. Introduction
The growing resistance of pathogenic bacteria to currently used drugs dictates an urgent search
for novel antibiotics. The antimicrobial peptides produced by the innate immune system of animals
or plants are considered as potential new agents to combat drug-resistant bacteria, since they have a
potent and rapid antimicrobial action and act via a multi-target mode of action. The innate immune
system plays a vital role in the host defense of invertebrates, in particular, as their adaptive immunity
is poorly developed, so that they have evolved a wide range of antimicrobial peptides (AMPs). Those
of marine invertebrates can be considered as one of the most promising sources of new and effective
antibiotics, especially AMPs from species inhabiting coastal zones, which are environments teeming
with microbes, where the peptides are vital to help them avoid infection.
The subject of our study is a cationic antimicrobial peptide, arenicin-1, from the coelomocytes
of one such invertebrate animal—the lugworm Arenicola marina [1]. This peptide adopts a β-hairpin
structure [2–4] and possesses a potent microbicidal activity towards a broad spectrum of Gram-negative
and Gram-positive bacteria (including drug-resistant clinical isolates), as well as towards fungi.
However, it also displays a substantial cytotoxicity towards mammalian cells [1–3]. The mechanism
of antimicrobial action of arenicin-1 is associated with a distinctive membranolytic activity [5–12].
Its potent antibiotic activity makes this peptide a fascinating lead for designing variants to test which
features determine the antimicrobial and/or cytotoxic capacities and to disclose if they can be in some
way extricated.
Though some of the structural characteristics of arenicins have already been explored,
the significance of an intriguing feature of this molecule—its pseudosymmetric residue
arrangement—remains unexplored (Figure 1).
Theβ-hairpin structures of arenicins show marked right-handed twist and kink in aqueous solution,
as revealed by NMR spectroscopy [2,4] as well as by molecular dynamics simulation [6]. These features
effectively allow the side chains of hydrophobic residues to be screened in an aqueous environment,
thus reducing the overall amphiphilicity of the peptide. In more anisotropic, membrane-mimicking
environments, arenicins form dimers stabilized by hydrogen bonds between parallel N-terminal
β-strands in two neighboring molecules [5]. Dimerization occurs at the membrane surface and induces
a substantial conformational change, so that the molecules adopt almost planar amphipathic β-sheet
structures [8,13]. This more regular conformation appears conducive to subsequent oligomerization
and membrane disruption and therefore appears to be a relevant feature for antibacterial activity.
Conformational regularity might be favored by an increased symmetry in residue arrangement.
The present study aimed to probe for a possible biological significance of the apparent residue
symmetry displayed by arenicin-1 molecules and to determine whether altering or increasing this
symmetry could result in improved antimicrobial characteristics, also in view of their potential as
leads for novel anti-infective agents. We furthermore wanted to test how an increased rigidity of the
β-hairpin could affect the biological properties as well as the roles played by specific residues.
Several variants of arenicin-1 were therefore elaborated for a structure–activity relationship study
to analyze the role of sequence symmetry, residue content, and conformational rigidity in microbicidal
efficacy, membranolytic activity, and cytotoxicity towards mammalian cells. We constructed a set
of peptides with a varying degree of symmetrization of the amino acid sequence and speculated
that this could result in a more planar arrangement of the peptide hairpin, with a reduction of the
kink and twist observed in the strands of the native peptide’s structure. To test this, we performed
extensive molecular dynamics simulations of the peptides, using different initial conformations, and
analyzed their folding capacity, stability, secondary structural features such as kink and twist angles,
and hydrogen bonding patterns.
Additional variants were also studied, in which key residues, such as the arginines that provide
the peptide’s charge or the tryptophan residues that flank the β-hairpin, were respectively replaced
with lysine and phenylalanine. We furthermore prepared a linear variant of arenicin-1 with reduced
and alkylated (iodoacetamidated) cysteine residues to probe the significance of the β-hairpin scaffold
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and, finally, a backbone-cyclized arenicin-1 analogue to explore if the increased rigidity that is likely to
result from this type of cyclization could affect activity and/or toxicity towards mammalian cells.
2. Results
Arenicin-1 (AR) adopts a characteristic β-hairpin structure stabilized by the presence of a disulfide
bridge and displays a peculiar symmetry in residue arrangement along the two strands (Figure 1). It is
a fascinating scaffold for designing variants to test features that may affect the molecule’s antimicrobial
and/or cytotoxic capacities.
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Figure 1. Pseudosymmetric sequence of the arenicin-1 molecule and structure of its designed analogues.
The hydrophobic residues are marked in blue, the polar residues are in red, and the palindromic
arrangement of the WCxxYxxVxVxxVxVxYxxCW motif in the initial arenicin-1 sequence is indicated
with rounded boxes. The VYYAYV(R) and (L)VRYRR motifs present in strands 1 and 2 of arenecin-1
are, respectively, highlighted by yellow and blue-grey boxes and were swapped (ARin-s), placed
symmetrically with inversion (ARs-N and -C), or branched from a central residue (ARsin-N-B and
ARs-C-B) in variants designed to test the role of the residue symmetry. Asterisks (*) in the linear version
of arenicin-1 (ARlin) mark the sites of Cys alkylation with iodoacetamide. Green arrows accentuate
the parallel arrangement of the strands in ARs-N-B and ARs-C-B peptides, obtained by linking the
“branches” of the hairpin to the α and δ amines of an ornithine residue (Orn), in turn coupled to an
amidated diaminopropionic acid (Dap) group at the C-terminus (Figure 7).
2.1. AR Variants Design
ARin-s was designed to alter the sequence symmetry by inverting the VYAYV and VRYRR
motifs, respectively present in the N- and C-terminal strands of wild-type AR (Figure 1). ARs-N
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had increased symmetry based on only the VYAYVR motif of the N-terminal strand; an additional
Arg residue was added to offset the decrease in overall charge that this entails. ARs-C, instead, had
increased symmetry based on the VRYRR motif of the C-terminal strand. To increase symmetry even
further, two non-proteinogenic variants—ARs-N-B and ARs-C-B—were constructed by branching
either the VYAYVRV sequence of strand 1 or the VLVRYRR sequence of strand 2 (fragments 1–10 and
13–21, respectively, Figure 1) from the α and δ amines of an ornithine (Orn) residue. This resulted
in a parallel arrangement of the hairpin strands, so that the obtained peptides had two N-termini.
The branching Orn residue was linked to an amidated diaminopropionic acid (Dap) residue at the
peptide’s C-terminus, in an attempt to maintain a structure of the branching site as far as possible
isosteric with the Arg residue normally present in the turn region (see Figure 7 in the Methods section).
We also constructed a backbone-cyclized version of AR (ARcycl) by linking the N-terminus to
the C-terminus using an innovative native chemical ligation (NCL) protocol. It has been reported
that the introduction of a second disulfide bridge in arenicin increases its rigidity and that this has
beneficial effects on both antimicrobial activity and toxicity [14]. However, this required replacing
internal residues (namely, Val8 and Val13) with Cys, while backbone cyclization of the N- and C-termini,
that are spatially close in the peptide β-hairpin, should be less invasive.
Additional variants were prepared with substitution of key residues. In AR-K, all Arg residues
were substituted with Lys to probe the relevance of these charged residues; analogously, in the
AR-F variant, Trp was replaced with Phe to probe the relevance of the flanking tryptophan residues.
Finally, we also prepared a linear variant of arenicin-1 with reduced and carboxamidomethylated
(iodoacetamidated) cysteine residues (RCM-Cys).
2.2. Assessing the Structure Using Molecular Dynamics Simulations
In our computational analysis of arenicin-1 analogues, we first developed a quantitative measure of
sequence symmetry by aligning the original and the inverted primary structures. As can be appreciated
from their sequences (Figure 1), the “branched” peptides ARs-N-B and ARs-C-B are ideal palindromes,
having not only identical sequences of both strands but also the same orientation.
We then performed an extensive molecular dynamics (MD) simulation of the peptides in an
aqueous environment to analyze their structure and dynamics. The peptides were modelled with
different starting conformations, in the presence or absence of the disulfide bonds. The linearized
version of the original arenicin-1, as well as the variant with reduced, carboxamidomethylated cysteines
(ARlin) and the linearized versions of the ARin-s and ARs-C variants, all demonstrated the ability to
fold rapidly from a fully extended linear conformation to a well-defined β-hairpin structure, which
was relatively stable even without the disulfide bond. The process of peptide folding was monitored
by measuring both the distance from the initial structure and the appearance of secondary structure
elements. The folding of ARs-C, with rapid emergence of the characteristic β-strands connected by
a turn, is shown in Figure S1. ARin-s and ARs-C were also modelled from more natural β-hairpin
starting structures, obtained using replica-exchange Monte Carlo simulations in the Quark program,
which also confirmed a high stability of this conformation even in the absence of the disulfide bond.
The ARs-N-B and ARs-C-B variants, instead, failed to fold from an initial extended linear
conformation, in the timescales used for our simulations. Therefore, we used a manually constructed
β-sheet structure with a disulfide bond to perform simulated annealing experiments. These resulted in
the formation of relatively flat β-sheet structures, which were further equilibrated by an additional
MD simulation. The resulting average structures obtained for all modelled peptides are shown in
Figure 2a, in which it can be clearly seen that the β-hairpin structures of ARin-s and ARs-C show the
same characteristic kink as AR, while the parallel β-hairpin of ARs-N-B and ARs-C-B are flatter and
less twisted.
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Figure 2. Average equilibrium structures obtained for all studied peptides by molecular dynamics
(MD) simulations. (a) Schematic ribbon representation, parallel and antiparallel β-strands are based on
secondary structure assignment by the STRIDE algorithm. (b) Structural alignment of ARlin, ARin-s,
and Ars-C with experimental arenicin-1 structure 2JSB. Only backbone atoms are shown, the coloring
matches panel (a).
The increase in sequence symmetry in the parallel β-stranded branched peptides made their
planar spatial structures the most distant from that of the original arenicin-1. Data on the structural
distance from the experimental arenicin-1 structure (root-mean-square deviation, RMSD), secondary
structure content, and average nu ber of ainchain hydrogen bonds for each peptide are provided
in Table 1. These show that the linearize ersi ith reduced, carboxyamidomethylated cysteines
(ARlin) formed a more distorted β-hairpin, with lower secondary st ucture content and greater distance
from the xperim ntal structure han the other an ipar llel β-hairpin structures. On the other hand,
the cyclic variant (ARcycl) and ARin-s were almost indistinguishable from the original a enicin-1,
as shown in the structural alignments in Figure 2b, so that the rearrangement of residues in the two
strands or backbone cyclizati did not seem to greatly affect the overall conformation. It is interesting
to note that the backbone cyclization can accommodate quite a tight cycle based on only five residues
(CWRWC), even though the three central residues are bulky, so that the motif could be quite rigid.
Table 1. Structural analysis of the resulting peptide models.
Peptide
(a) Cα RMSD with 2JSB
(Å)
(b) Average N◦ of
H-Bonds (±SD)
(c) Average 2y Structure
Content
AR 1.37 8.3 ± 1.2 14/21
ARin-s 1.67 8.3 ± 1.2 16/21
ARs-C 1.90 6.4 ± 1.1 14/20
ARs-N-B 4.29 7.1 ± 1.3 13/22
ARs-C-B 3.30 6.2 ± 1.1 10/20
ARlin 3.13 5.4 ± 1.2 9/21
ARcycl 1.57 7.1 ± 1.2 16/21
(a) Root-mean-square deviation (RMSD) of the coordinates of Cα atoms in variant structures of the experimental
arenicin-1 NMR structure. (b) Average number (N◦) of mainchain H-bonds calculated from the equilibrium parts of
the MD trajectories. (c) Ratio of residues in antiparallel or parallel β-sheet conformation assigned by the STRIDE
algorithm to the to N◦ of residues. 2JSB: P otein Data Bank (PDB) ID of arenicin-1.
The parallel, branched β-hairpin peptides ARs-N-B and ARs-C-B were structurally the most
distant from the original conformation, with RMSD > 4 Å for ARs-N-B. Moreover, although the average
number of intramolecular main-chain hydrogen bonds was similar for all peptides, AR, ARin-s, ARs-C
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displayed the standard hydrogen bonding pattern of an antiparallel β-sheet (Figure 3), while ARs-N-B
and ARs-C-B showed a bonding pattern characteristic of a parallel β-sheet. Supposedly, this difference
in intramolecular hydrogen bonding could affect also intermolecular H-bonding and so alter the
mechanism of dimerization and oligomerization on the membrane surface.
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Figure 3. Different hydrogen bonding patterns observed for arenicin variants. AR, ARin-s, and ARs-C
show the same H-bon in pattern (dotted blue lines) typical of antiparallel β-strands (two H-bonds
connect t e α-amine a α-carboxyl groups of a amino acid o one side of the hairpin with the
α-amine and α-carboxyl groups of an amin acid on the other side of the hairpin). ARs-N-B and
ARs-C-B instead show the pattern typical f parallel β-strands (tw H-bonds connect the α- mine and
α-carboxyl groups of an mino acid on one side of the hairpin with the α-ami and α-carboxyl groups
of tw different amino cids on the other i ). The disulfide bond is indicat d by a solid grey line, as
well as branching from the ornithine residue α- and δ-amin s (Figure 7).
The structural stability of the peptides was analyzed by calculating the fluctuations
(root-mean-square fluctuati ns, RMSF) of the backbone Cα atoms at equilibrium. All peptides
demonstrated a fluctuation pattern typical of a β-sheet with a higher mobility at the ter i i and ne r
the turn connecting he two β-strands (Figure S2a). The peptide ARs-C-B exhibited a remarkably
high structural stability, with low fluctuations ev n on th β-strand term n . This b h vior could be
at ibuted to n additional stabiliza ion due to stacking of two N-terminal tryptophan residues, which
is shown in Figure S2b.
Finally, we analyzed the effect of sequence symmetry on the overall geometry of the peptide. For
each peptide, determined the average twist and kink angles from the equilibrium parts of the MD
trajectories. We then plo ted th twist nd kink angles versus sequence symmetry for each peptide, as
shown in Figure 4. As expected, and in agreement with the MD simulations, the or s mmetrical
sequences of ARs-N-B and ARs-C-B resulted in significantly lower twist and kink of the peptid s,
which both had nearly planar parallel β-hairpin structures, quite distant from the original arenicin-1
structure and rather uncommon for β-hairpin peptides, which cannot by, definition, have symmetric,
parallel β-strands.
Mar. Drugs 2019, 17, 376 7 of 21Mar. Drugs 2019, 17, x FOR PEER REVIEW 7 of 21 
 
 
Figure 4. Average kink (a) and twist (b) angles for the peptides as a function of their sequence 
symmetry. Sequence symmetrization in ARs-N-B and ARs-C-B results in significantly lower kink and 
twist. 
2.3. Antimicrobial Activity 
We tested the antimicrobial activity of the peptides against a set of Gram-negative and Gram-
positive bacteria, including drug-resistant clinical isolates. As shown using the broth microdilution 
assay (Table 2), the peptide with inverted symmetry (ARin-s) had a reduced activity against Gram-
negative strains and lost activity against Gram-positive ones. This may be due to the replacement of 
the VYAYV motif in the N-terminal strand, which is reported to be important for oligomerization, 
with the inverted C-terminal motif RRYRVL. However, the fact that the variant with a symmetrically 
placed RRYRVL motif in both strands (ARs-C) maintained a substantial activity, while the one with 
a symmetrically placed VYAYV motif lost activity, suggests that this type of oligomerization is only 
one of the factors determining activity and that the C-terminal strand may also have a significant role. 
ARs-C (+7) may act as a monomer for which the higher charge is beneficial, and while we attempted 
to maintain a reasonable cationicity (+5) for ARs-N by adding an Arg residue at the N-terminus, it 
was still reduced with respect to arenicin-1 (+6). It is interesting that the same trend was observed for 
the “branched” variants, where ARs-C-B (+9), based on the RRYRVL motif of the C-terminal strand, 
was more active than ARs-N-B (+7), based on the VYAYV motif of the N-terminal strand, but the 
latter becomes significantly more active than the less cationic ARs-N peptide based on a canonical 
antiparallel β-hairpin. 
The backbone-cyclized and linear versions of arenicin-1, as well as the peptides with Arg 
replaced with Lys (AR-K) and Trp replaced with Phe (AR-F), showed an antimicrobial activity 
comparable with that of the native peptide. However, it was not possible to determine from the 
minimal inhibitory concentrations (MIC) values alone if and how the mechanism of action had 
changed. One may simply suggest that it continued to involve an initial interaction with the 
membrane determined by electrostatic interactions and that the subsequent insertion into the 
membrane was due to the presence of hydrophobic residues, but the mechanism of the subsequent 
membrane permeabilization (which involves peptide oligomerization) could be affected. Our MD 
simulations would in any case suggest that the β-hairpin structure was maintained in all these 
variants, even the linear one, with a strong propensity for the scaffold to fold into this conformation. 
It is interesting to note that, while altering the symmetry reduced the antimicrobial activity against 
drug-resistant clinical isolates in particular, backbone cyclization of arenicin-1 resulted in improved 
activity towards these isolates. 
To obtain a global assessment of the effect on antimicrobial activity, the geometric mean of the 
MIC (G-MIC) was calculated, and from this, the overall improvement or impoverishment with 
respect to arenicin-1. In general, inverting the symmetry or decreasing the charge had detrimental 
effects. Turning the peptide into a parallel β-hairpin also did not improve activity. Linearizing the 
peptide did not seem to significantly affect its activity, while substituting Lys for Arg and Phe for Trp 
seemed to slightly improve it. Taken together, these results suggest that these modifications did not 
Figure 4. Average kink (a) and twist (b) angles for the peptides as a function of their sequence symmetry.
Sequence symmetrization in ARs-N-B and ARs-C-B results in significantly lower kink and twist.
2.3. Antimicrobial Activity
We tested the antimicrobial activity of the peptides against a set of Gram-negative and
Gram-positive bacteria, including drug-resistant clinical isolates. As shown using the broth
microdilution assay (Table 2), the peptide with inverted symmetry (ARin-s) had a reduced activity
against Gr m-negative strains and lo t activity against Gram-positive ones. This may be due to the
replacement of t VYAYV motif in th N-ter inal strand, which is reported to be important for
oli omerization, with the inverted C-termin l motif RRYRVL. However, the fact that th v riant with
a symmetrically placed RRYRVL motif i bot strands (ARs-C) maintained a substantial activity,
hile the one with a symmetrically placed VYAYV motif lost activity, suggests that this type of
oligomerization is only one f the factors determining ctivity and that the C-terminal strand may also
have a significant role. ARs-C (+7) may act as a monomer for w ich the higher charge is beneficial, a d
while we attempted to aintain a reaso able cationicity (+5) for ARs-N by adding an Arg residue at
the N-terminus, it w still reduc d with respect to arenicin-1 (+6). It is interesting t at the s me tren
was observed for the “branched” variants, where ARs-C-B (+9), based on the RRYRVL motif of the
C-terminal strand, was more active than ARs-N-B (+7), ba ed on the VYAYV motif of the N-terminal
strand, but the latter becomes significantly more active than the less cationic ARs-N peptide b sed o a
canonical antiparallel β-hairpin.
Th backbone-cyclized and linear rsions of ar nicin-1, as well as the eptides with Arg replaced
with Lys (AR-K) and Trp replaced with Phe (AR-F), showed an antimicrobial activity comparable with
that of the native peptide. However, it was n t possibl to determine from t minimal inhibitory
concentrations (MIC) values alone if and how the mechanism of action had changed. One ma
simply suggest t at it c ntinued to involve an initial interaction with the m mbran determined by
electrostatic interactions and that the subsequent insertion into the membrane was due t the presence
of hydrophobic residues, but the mechanism of the subseque t membrane permeabilization (which
involves peptid oligomerization) could be affected. Our MD simulations would in any case suggest
that the β-hairpin structure was maintained in all these variants, ev n the li ear one, with a strong
propensity for th scaffold to fold into this conformation. It is interesting to note that, while altering
the symmetry reduced the antimicrobial activity against drug-resistant clinical isolates in p rticular,
b ckbone cyclizatio of arenicin-1 resulted in improved activity towards these is lates.
To obtai a global assessment of the effect on antimicrobial activity, the ge metric mean of the
MIC (G-MIC) was calculated, and from this, the overall improvement or impoverishment with respect
to arenicin-1. In general, inverting the symmetry or decreasing the charge had detrimental effects.
Turning the peptide into a parallel β-hairpin also did ot improve activity. Linearizing the peptide did
not seem to significantly affect its activity, while substituting Lys for Arg and Phe for Trp seemed to
slightly improve it. Taken together, these results suggest that these modifications did not markedly
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improve the already potent antibacterial activity of the parent peptide but rather subtly alter its
activity spectrum.
Table 2. Antimicrobial activity of the arenicin-1 variants (broth microdilution assay).
Minimal Inhibitory Concentrations (MIC) a, µM
AR ARin-s ARs-N ARs-C ARs-N-B ARs-C-B AR K AR F ARlin ARcycl
Gram-negative laboratory strains
Escherichia coli ML35p 1–2 4–8 16 1 4 1–2 1 1 1–2 1–2
E. coli ATCC 25922 2 8 >16 2 8 4 2 1 2 2
E. coli M15 2 8 >16 2 4 8 1 1 2 2
Pseudomonas aeruginosa
ATCC 27853 2 4–8 >16 1 2 1 1–2 1 2 1
Gram-positive laboratory strains
Listeria monocytogenes EGD 1–2 2 8 1 2–4 2 2 2 2 2
Staphylococcus aureus 710A 2 16 >16 2–4 8 4 2 2 2 2
S. aureus ATCC 25923 2 16 >16 4 8 4 2 2 2 2
MRSA ATCC 33591 4 >16 >16 4–8 8 8 2 2 4 4
Clinical isolates
P. aeruginosa c.i. 4 >16 >16 16 16 16 2–4 2 4–8 2
Acinetobacter baumanii c.i. 4 16 >16 2 4 8–16 1 2 4 4
Staphylococcus intermidius 8 >16 >16 8 8 4 4 4 8 4
S. aureus c.i. 4 >16 >16 16 8 4–8 4 4 8–16 4
Overall statistics
G-MIC b 2.7 ≥12.8 ≥26.9 3.2 5.9 4.4 1.9 1.8 3.1 2.3
G-MIC improvement ratio
in comparison with AR c 1.0 ≤0.2 ≤0.1 0.8 0.5 0.6 1.4 * 1.5 * 0.9 1.2 *
a Minimal inhibitory concentrations (MIC) values were derived from 3–5 experiments which were performed in
triplicates. b Geometric mean of the MIC (G-MIC) is the geometric mean of all determined MICs; the median values
of MICs were used for calculation. In the case of MIC > 16 µM, the next concentration in the series of two-fold
dilutions (32 µM) was used for G-MIC assessment. c As the lower MIC corresponds to the higher activity, MIC
improvement was calculated as a ratio of G-MIC of native arenicin (AR) to G-MIC of the peptide of interest. *:
higher overall activity, compared to AR.
2.4. Effect of Arenicin Variants on Bacterial Membrane Integrity
The Escherichia coli ML35p strain expresses a plasmid-encoded periplasmic β-lactamase and
is constitutive for cytoplasmic β-galactosidase, while lacking lactose permease [15]. This makes it
very useful to monitor the permeabilization of both its outer and inner membranes, using real-time
assays. From Figure 5, it can be seen that the outer membrane became fully permeable to nitrocefin, a
β-lactamase substrate, ~30 min after adding most arenicin-1 analogs. However, all variants with a
modified symmetry demonstrated a decreased ability to permeabilize the inner membrane of E. coli
ML35p, suggesting a reduced membranolytic activity.
It is interesting to note that, whereas some variants did show an improved capacity to permeabilize
the outer membrane with respect to arenicin-1 (e.g., AR-K and ARcycl), none of the variants (with the
possible exception of AR-F) showed an improved capacity to permeabilize the cytoplasmic membrane.
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2.5. Cytotoxicity of Arenicin-1 Variants towards Mammalian Cells
The toxicity of arenicin peptide variants towards eukaryotic cells was tested using the MTT assay
on the human erythroleukemia cell line (K-562). The arenicin variants with Arg-to-Lys (AR-K) and
Trp-to-Phe (AR-F) substitutions, which exerted a slightly improved antimicrobial activity compared to
the native peptide (see Table 2), were also found to be somewhat more cytotoxic, the half-maximal
inhibitory concentration (IC50) decreasing by a factor of 2 (Table 3). This is quite typical of membranolytic
AMPs, for which a higher antibacterial activity is often accompanied by an increased toxicity to host
cells [16,17].
The cytotoxic activity of the backbone-cyclized variant ARcycl and of variants modified to increase
the symmetry in an antiparallel β-sheet structure (ARs-N and ARs-C) was comparable (ARcycl, ARs-N)
or only moderately increased (ARs-C), with respect to that of the original pe tid . On the other hand,
both of the “branched” symmetrical variants (ARs-N-B and ARs-C-B) and the linearized arenicin
(ARlin) showed at least a two-fold reducti of cytotoxicity. The same was observed for ARin-s with
inverted symmetry, but in this case, it was accompanied by a significantly lower antibacterial activity.
The impact of the peptides on eukaryotic membranes was also analyzed using the hemolysis
assay, with peptide concentrations up to 80 µM (Figure 6). None of the modifications completely
abolished the relatively high hemolytic activity of wild-type arenicin, although the branched variant
based on the C-terminal motif (ARs-C-B), which was moderately active on bacteria, demonstrated a
significantly lowered ability to lyse the erythrocytes. On the other hand, other variants with improved
antimicrobial activity (e.g., AR-F and AR-K) did not show a significantly increased hemolytic activity,
based on the HC50 value.
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Table 3. Cytotoxic effects of arenicin-1 variants towards human erythroleukemia K-562 cells and
human erythrocytes.
Effects of the Peptides
AR ARin-s ARs-N ARs-C ARs-N-B ARs-C-B AR-K AR-F ARlin ARcyclic
Cytotoxicity towards K-562 cell line (human erythroleukemia cells)
IC50a, µM (MTT-assay) 17.9 37.7 18.0 11.6 35.1 39.0 7.7 9.3 >40 16.2
SI1 assessment
IC50/G-MIC
6.6 ≤2.9 ≤0.7 3.6 6.0 8.8 4.0 5.2 >12.8 7.0
SI1 improvement ratio in
comparison with ARb 1.0 ≤0.4 ≤0.1 0.5 0.9 1.3 * 0.6 0.8 >1.9 * 1.1
Hemolysis of human red blood cells
HC50c, µM 66.3 >80 >80 66.0 >80 >80 63.0 60.5 >80 65.5
SI2 assessment
HC50/G-MIC
24.6 - - 20.6 >13.7 >18.1 33.1 34.0 >25.6 28.2
SI2 improvement ratio in
comparison with ARb 1.0 - - 0.8 >0.6 >0.7 1.3 1.4 >1.0 1.1
HC15c, µM 10.3 17.2 23.5 11.8 12.4 56.4 10.1 10.6 29.9 14.0
SI3 assessment
HC15/G-MIC
3.8 ≤1.3 ≤0.9 3.7 2.1 12.7 5.3 6.0 9.5 6.0
SI3 improvement ratio in
comparison with ARb 1.0 ≤0.4 ≤0.2 1.0 0.6 3.3 * 1.4 1.6 2.5 * 1.6
a Half-maximal inhibitory concentration (IC50) was calculated using Sigma Plot Standard Curve Analysis based on
3–4 independent experiments. b Selectivity index (SI) improvement was calculated as a ratio of the SI of the peptide
of interest to the SI of native AR. The peptides with the highest SI values are the least cytotoxic. c Half-maximal
hemolytic concentration (HC50) and 15% maximal hemolytic concentration (HC15) were calculated using Sigma Plot
Standard Curve Analysis based on 3–8 independent experiments. *: variants with the most significant reduction of
toxicity in both hemolysis and MTT-test, compared to AR.
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We used both the MTT and hemolysis data to make an in vitro estimate of selectivity indices
(SI) of the peptides (see Table 3), as these help characterize the width of the ‘therapeutic window’ of
a compound and thus its suitability for possible therapeutic application. We used the G-MIC as a
measure of the overall antimicrobial activity of the peptides (see Table 2) and the half-maximal MTT
inhibitory concentration (IC50) or half-maximal hemolytic concentration (HC50) as a measure of their
toxicity. In the case of hemolytic activity, only 5 of the 10 investigated variants reached their HC50 at a
concentration of 80 µM, which somewhat limited the SI assessment. For a more precise comparison of
the SI, we therefore calculated the HC15, a hemolysis level which could be reliably calculated for all
tested peptides on the basis of the experimental data (Figure 6). Both hemolysis- and MTT-derived
selectivity index estimates (SI1 and SI3, see Table 3) indicated that the branched symmetrical arenicin-1
variant based on the C-terminal motif (ARs-C-B) and the linearized arenicin (ARlin) possessed the
best combination of antibacterial and cytotoxic properties, amongst the tested arenicin-1 analogues.
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ARs-C-B showed over a three-fold improvement in SI3 compared with native arenicin. The variants
with the poorest SI characteristics were the one with inversed symmetry (ARin-s: low antimicrobial
activity but relatively high cytotoxicity) and the N-terminal motif-based symmetrical arenicin ARs-N.
3. Discussion
Marine animals are recognized as a rich source of potentially useful novel bioactive substances,
including new anti-infective drugs. Several AMPs from marine invertebrates have been described to
date, such as the penaeidins from shrimp [18], mytilins from mussels [19], aurelin from jellyfish [20],
tachyplesins from the horse-shoe crab [21], arasin from the spider crab [22], and several others. One of
the most potent AMPs is arenicin-1, from the lugworm A. marina [1]. However, to be suitable as a
lead compound for drug development, this highly active peptide requires optimization, as it is also
significantly hemolytic.
We observed that this peptide possesses a rather unique pseudosymmetric structure and explored
the significance of this feature with respect to its antimicrobial activity as well as its cytotoxicity for
mammalian cells. This peptide presents two Trp residues at each terminus and three Tyr residues
distributed along the β-strands. A study of other tryptophan-rich peptides, such as the bovine,
cathelicidin-derived peptides tritrpticin and indolicidin, has shown that sequence symmetrization
can result in improvement of the antimicrobial activity, accompanied by a decreased hemolytic
action [23]. A zipper-like symmetric arrangement of aromatic residues along the strands can also
increase the stability of β-hairpin AMPs, increasing their activity [24]. Furthermore, synthetic,
disulfide-stabilized, β-hairpin peptides based on symmetric sequences of a VR motif also provide an
appreciable, broad-spectrum antimicrobial activity with a membranolytic mechanism [25].
For these reasons, several arenicin-1 variants with increased or modified symmetry, as well as with
changes in other primary structural features, have been designed (Figure 1), chemically synthesized,
and investigated. Molecular dynamics simulations allowed us to predict possible effects on the
structures of these variants and to analyze their conformational stability and dynamics. A linearized
version of arenicin-1, as well as two variants with β-strand permutations, ARin-s and ARs-C, showed
a rapid and robust folding into a well-defined β-hairpin structure that showed a remarkable similarity
with the experimentally determined structure of the parent peptide arenicin-1. The RMSD was
relatively low (1.6–1.9 Å, Figure 2b), and the hydrogen bonding pattern between the flanking β-strands
was the same (Figure 3), so that the overall geometric parameters, twist and kink angles, were
virtually indistinguishable from those of arenicin-1. These simulations suggested that permutations of
whole β-strands, including palindromic symmetrization, did not significantly affect the characteristic
β-hairpin structure of the scaffold, although switching the VYAYV and RRYRVL motifs between N-
and C-terminal strands (as in ARs-in), might affect the mechanism of self-association in a membrane
environment, which is reported to involve the N-terminal strand of the native peptide.
On the other hand, MD simulations on peptides with a non-canonical, branched, parallel β-hairpin
arrangement achieved by chemical synthesis supported our hypothesis that an increased symmetry in
the primary structure would translate into a more symmetrical β-structure, with reduced twist and kink
angles. For the two highly symmetric analogues of this type (ARs-N-B and ARs-C-B), the β-hairpin
became almost flat, and the hydrogen bonding pattern between the strands was altered (Figure 3).
This would result in a different pattern of vacant hydrogen donor/acceptors on the other side of the
peptide’s β-strands, also affecting intermolecular contacts. Considering that native arenicin molecules
form dimers by a parallel association of the N-terminal β-strands [5,11], the branched variants could
have an altered oligomerization propensity and, therefore, a modified pore-forming activity. Their
biological activity might be reduced.
In effect, the structure–antimicrobial activity relationship of arenicin-1 turned out to be rather
robust, with all studied variants, except ARin-s (with an inverted strand arrangement) and the
symmetrical variant ARs-N (with reduced charge), maintaining an appreciable activity against both
Gram-negative and Gram-positive bacteria, including drug-resistant strains. The charge dependence
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of the activity for ARs-N (+5) was also suggested by the fact that the activity was partly re-established
for the parallel-stranded analog ARs-N-B (+7), which is supported by similar observations for other
AMPs [26,27]. The activity loss in ARin-s is significant, and as the secondary structure was modelled
to be very similar to that of the parent peptide, could be due either to the altered residue arrangement
or to a reduced propensity of the altered N-terminal strand to dimerize in the membrane.
The cytotoxic action of arenicin-1 variants towards mammalian cells was less sensitive to the
molecule’s charge and more sensitive to its symmetry and three-dimensional organization. The flatter,
symmetrically branched peptides ARs-N-B and ARs-C-B were less toxic to K-562 cells by a factor
of two than the native peptide, whereas ARs-N and ARs-C—with a more pseudo-symmetric but
antiparallel β-hairpin conformation—showed a comparable or slightly increased cytotoxicity. When
native arenicin-1 dimerizes by the parallel association of its N-terminal strands, it adopts a more planar
conformation [5,11]. The intrinsically more planar conformations of ARs-N-B and ARs-C-B might
thus be expected to favor oligomerization, and in line with several studies, an increased propensity
for self-association in solution should correlate with increased cytotoxicity [23,28,29]. The fact that
these analogs showed both a reduced bacterial membrane permeability (Figure 5) and host cell
cytotoxicity, compared to the parent peptide, suggests that this was not the case. Possibly, the different
intramolecular H-bonding patterns of the parallel branches in the modified peptides affected their
capacity to form the intermolecular H-bonds.
Analysis of other variants revealed that an improvement of the in vitro antimicrobial activity
could be obtained by Arg-to-Lys (AR-K) or Trp-to-Phe (AR-F) substitutions, but at the expense of an
even more prominently increased toxicity towards mammalian cells. Interestingly, other reports on
Arg-to-Lys substitutions in AMPs [30,31] suggest that the arginine side chain can form more hydrogen
bonds and thus interact more strongly with phospholipid components of bacterial membranes, with
respect to lysine, which should enhance the activity of Arg-rich AMPs with respect to the Lys-rich
analogues [31,32]. Previously published data on an arenicin-1 analogue with Arg-to-Lys substitutions
indicated that the activity of this peptide is comparable to that of the parent AR, but in a salt-, medium-
and bacterial species-dependent manner [7].
The replacement of Trp with Phe may favor the insertion of the AR-F peptide into membranes
but it does not seem to discriminate between bacterial and eukaryotic membranes. Furthermore, it is
reported that the kinked arenicin-1 hairpin becomes significantly flatter upon membrane contact and
oligomerization [5]. Molecular dynamics simulations with ARs-C-B indicated that Trp stacking in
parallel strands may contribute to stabilizing the flattened conformation.
The backbone-cyclized analogue of arenicin-1 acted similarly to the parent peptide towards both
bacterial and mammalian cells, while the linear variant showed a higher selectivity for the bacterial
cells. The macro-cyclization of AMPs has been reported to reduce the toxicity of some AMPs towards
host cells (e.g., protegrin 1, tachyplesin 1, and gomesin AMPs [33–35]), but in the case of arenicin,
it did not substantially alter the biological activity. In fact, as it occurs close to the disulphide bridge,
it results in a rather tight, five-residue cycle (CWRWC), which could be quite rigid considering the
steric bulk of the central residues. MD simulations with the linear AR variant showed that it has a
strong propensity to fold to a β-hairpin even in the absence of a disulphide bridge, which suggests that
backbone cyclization could replace disulphide bridging to stabilize the peptide, freeing the positions
of the Cys residues for variations that may improve its activity. This has been observed for macrocyclic
antimicrobial conotoxin analogues with replaced cysteines [36].
With respect to the linearized arenicin, a variant with the replacement of cysteine residues
with serine has previously been reported and was shown to have a 2–4-fold decreased antimicrobial
activity [3,7]. Our linearized analogue, with alkylated cysteine residues, instead substantially maintained
the antimicrobial activity. As MD simulations suggested, it also displays a substantial propensity to fold
to a β-hairpin conformation, albeit with a reduced stability with respect to the parent peptide; it may
also maintain some of its capacity to oligomerize and permeabilize bacterial membranes. In any case,
studies on other linearized β-hairpin AMPs with reduced Cys or Cys replaced with Ser (e.g., bovine
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cyclic dodecapeptide [37] and porcine protegrin 1 [38]) indicate that, while activity may be reduced to
some extent, it is not entirely abrogated. In fact, some linearized analogues of bovine dodecapeptide
(bactenecin 1) demonstrated a potent antibacterial action and higher selectivity for bacterial cells than the
parent peptide [39]. Studies with cyclic, linear, or dimeric (parallel and antiparallel) cyclic dodecapeptide
suggest that the antimicrobial activity is quite robust and retained to some extent by all these forms,
even though characteristics such as the salt-dependence of the activity can vary [40].
4. Materials and Methods
4.1. Peptide Synthesis
4.1.1. Antiparallel β-Hairpins
Solid-phase peptide synthesis of most variants was performed on a microwave-enhanced CEM
Liberty synthesizer (Charlotte, NC, USA), loaded with Trp-substituted, 2-chlorotrityl chloride resin
(substitution of 0.2 mmol/g). Insertion of the C-terminal Trp was performed manually according to
the instructions provided in the synthesis notes section (section 2.17) of the Novabiochem catalogue.
Double coupling was affected at all positions, with a four-fold excess of fluoren-9-dymethoxycarbonyl
amino acid/HATU/diisopropylethylamine (1:1:1.7, by vol.) at 70 ◦C. For couplings involving Cys,
the temperature was limited to 50 ◦C. Branched peptides (ARs-N-B and ARs-C-B) were synthesized
as amides, using the NovaPEG Rink Amide resin (substitution 0.22 mmol/g). Diamminopropionic
acid (Fmoc-DAP(Boc)-OH) was loaded as the C-terminal residue, followed by (Fmoc-Orn(Fmoc)-OH)
and then branching from the Orn residue. Peptides were cleaved from the resin and deprotected
using a cocktail consisting of trifluoroacetic acid (TFA), water, ethanedithiol, triisopropylsilane mixture
(94:2.5:2.5:1, by vol.). The free peptides were precipitated and washed with t-butyl methyl ether and
dried under nitrogen.
4.1.2. Branched, Parallel Hairpins, and Simulation of the Turn Region
While the primary structure of the native peptide imposed an antiparallel arrangement of the
strands in the β-hairpin [2], the synthetic variants with the parallel prongs of the hairpin were
designed to achieve a more symmetric arrangement of the peptide molecule. In the design of these
“branched” peptides, it was attempted to maintain a structure of the branching site as far as possible
isosteric with the Arg residue normally present in the turn (Figure 7), by branching from an ornithine
(Fmoc-Orn(Fmoc)-OH) coupled to a C-terminal Dap amide (Fmoc-Dap(Boc)-OH) coupled to a Rink
amide resin]. The synthesis and cleavage were carried out in the same conditions as for the β-hairpin
peptides. ARs-N-B and ARs-C-B have identical co-directional prongs in the two parallel strands of the
branched peptide, based, respectively, on the N- or C- terminal strands of arenicin.
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tris(2-carboxyethyl)phosphine (TCEP) to ensure the Cys residues were reduced, and left for 1 h. The 
backbone-cyclized peptide was then purified by RP-HPLC and resuspended in folding buffer (pH 
8.5), and the disulphide bridge was formed as described below. 
4.1.4. Disulphide Bond Formation 
Disulphide bonds in the arenicin variants were formed by adding the peptides to a freshly 
prepared N2-saturated aqueous buffer (1 M guanidinium chloride/0.1 M ammonium acetate/2 mM 
EDTA, pH 8.5) in the presence of 1 mM cysteine and 0.1 mM cystine. The final peptide concentration 
was kept below 10 µM to avoid dimer formation, and oxidation was carried out overnight. The linear 
variant of arenicin-1 was obtained by means of reduction of the parent AR followed by alkylation of 
the reduced peptide with iodacetamide using a standard protocol. 
Folding was monitored by analytical RP-HPLC (GE Life Sciences Äkta FPLC 900 Pittsburg, PA, 
USA) using a Waters Symmetry® C18 column (3.5 µm, 100 Å, 4.6 mm × 50 mm), and after completion, 
the final desalting and purification were carried out using a Waters Delta-Pak® C18 column (15 µm, 
300 Å, 25 mm × 100 mm). Gradients were typically 5%–55% acetonitrile in H2O (0.05% trifluoroacetic 
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Figure 7. Sequence of the turn region of native arenicin (–VRGV–) and simulated turn region of the
“branched” arenicin 1 variants (–VOrn(δ)V–) where the Orn α-amine is coupled to amidated Dap.
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4.1.3. Backbone-Cyclized Arenicin
The cyclic variant (ARcycl) was synthesized using the same Trp-substituted, 2-chlorotrityl chloride
resin (substitution of 0.2 mmol/g), but with the sequence Boc–CVYAYVRVRGVLVRYRRCW, to provide
an N-terminal Cys residue for native chemical ligation. The methodology has been described previously
for native ligation of two peptide fragments [41] and was adapted for backbone cyclization. Briefly, the
fully protected peptide carboxylic acid (including Boc-protected N-terminus) was cleaved from the
resin with hexafluoroisopropanol (HFIP) in dichloromethane (DCM), and the product was esterified
to the corresponding 4-acetamidophenyl-thioester, according to a published procedure [42,43]. After
acid deprotection of this peptide thioaryl ester with a thiol free cleavage mixture, it was suspended to
a concentration of 30 mM in a solution of 6 M guanidinium hydrochloride, 100 mM sodium acetate,
2 mM EDTA in the presence of 10 eq. of tris(2-carboxyethyl)phosphine (TCEP) to ensure the Cys
residues were reduced, and left for 1 h. The backbone-cyclized peptide was then purified by RP-HPLC
and resuspended in folding buffer (pH 8.5), and the disulphide bridge was formed as described below.
4.1.4. Disulphide Bond Formation
Disulphide bonds in the arenicin variants were formed by adding the peptides to a freshly
prepared N2-saturated aqueous buffer (1 M guanidinium chloride/0.1 M ammonium acetate/2 mM
EDTA, pH 8.5) in the presence of 1 mM cysteine and 0.1 mM cystine. The final peptide concentration
was kept below 10 µM to avoid dimer formation, and oxidation was carried out overnight. The linear
variant of arenicin-1 was obtained by means of reduction of the parent AR followed by alkylation of
the reduced peptide with iodacetamide using a standard protocol.
Folding was monitored by analytical RP-HPLC (GE Life Sciences Äkta FPLC 900 Pittsburg, PA,
USA) using a Waters Symmetry®C18 column (3.5 µm, 100 Å, 4.6 mm × 50 mm), and after completion,
the final desalting and purification were carried out using a Waters Delta-Pak®C18 column (15 µm,
300 Å, 25 mm × 100 mm). Gradients were typically 5%–55% acetonitrile in H2O (0.05% trifluoroacetic
acid) for 30 min. The correct structure and purity were confirmed by ESI–MS using a Bruker Daltonics
Esquire 4000 mass spectrometer (Billerica, MA, USA), working in positive mode, directly on the
eluate fractions.
4.2. Molecular Modeling
4.2.1. Molecular Dynamics Simulations
All MD simulations were performed with the Gromacs-4.5.4 software package [44] with GROMOS
43a2 forcefield [45]. Two types of initial conformations were used to simulate the folding and dynamics
of the peptides: an extended linear conformation and a β-sheet structure. The preparation of the
initial conformations is described in Supplementary materials. The topologies for ornithine and
diaminopropionic acid in ARs-N-B and ARs-C-B were constructed manually, analogously to a lysine
residue. The linearized version of arenicin-1 (ARlin) had reduced, carboxamidomethylated cysteines
(RCM-Cys), and the cyclic variant (ARcycl) had an additional peptide bond between the terminal
residues. All calculations utilized periodic boundary conditions. Long-range electrostatic interactions
were computed by the particle-mesh Ewald (PME) method. The cut-off for non-bonded van der Waals
interactions was set to 1.2 nm. Each system was first energy-minimized by 5000 steps of steepest
descent. Energy minimization was followed by two 100 ps equilibration runs using NVT and NPT
ensembles during which the positions of peptide atoms were restrained by a harmonic potential with
a force constant of 1000 kJ·mol−1·nm−2. The equilibration was followed by 50–120 ns production
MD runs integrated with a 2 fs timestep. During the MD simulations, temperature was maintained
at 300–315 K by a Nose–Hoover thermostat with a time coupling constant 0.5 ps, and pressure was
maintained at 1 atm by a Parrinello–Rahman barostat with a time coupling constant 2.0 ps. In the
case of the peptides ARs-N-B and ARs-C-B, we also performed a periodic simulated annealing with
temperatures at 300–365 K. The coordinates were written to an output trajectory file every 2 ps for
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further analysis. The resulting MD trajectories and the corresponding simulation parameters are
summarized in Table S1.
4.2.2. Analysis of the Simulation Results
The analysis of the MD trajectories was done using various utilities in the Gromacs package.
To monitor the folding process, we calculated the RMSD of Cα carbon atoms from their initial
positions. The evolution of the secondary structure was followed using the DSSP structure assignment
program [46]. The stability and dynamics of the peptides were accessed by calculating RMSF of Cα
carbon atoms and the average number of hydrogen bonds at the tail of a MD trajectory, where the
system reached equilibrium. The same equilibrium parts of the trajectories were used to clusterize
the conformations and determine the mean peptide structures. These mean structures were used to
estimate the structural similarity with arenicin-1 by calculating the RMSD with experimental NMR
structure PDB: 2JSB and to determine the secondary structure content by the STRIDE algorithm [47].
The kink and twist angles were analyzed analogously to a previous work on molecular dynamics
simulation of arenicin-2 [6]; the details of the analysis methodology are given in Supplementary
materials (Supplementary Chapter S1, [4,48–50]). The figures of the peptides were prepared using
PyMol [49].
4.3. Antibacterial Assays
4.3.1. Bacterial Strains
E. coli ML35p, Listeria monocytogenes EGD, methicillin-resistant Staphylococcus aureus (MRSA)
ATCC 33591 were kindly provided by Prof. Robert Lehrer (University of California, Los Angeles,
CA, USA); E. coli ATCC 25922, E. coli M15, Pseudomonas aeruginosa ATCC 27853, S. aureus ATCC
25923 were provided by Dr. Elena Ermolenko (Institute of Experimental Medicine, St-Petersburg,
Russia); drug-resistant clinical isolates were provided by Prof. Gennadiy Afinogenov (Saint Petersburg
State University, Russia); S. aureus 710A has been described previously [51]. The following clinical
isolates of bacteria were used: P.s aeruginosa resistant to aztreonam, ceftazidime, cefotaxime (obtained
from the urine of a patient with cystitis), Acinetobacter baumannii resistant to meropenem (from an
infected wound); Staphylococcus intermedius (from an infected wound caused by a dog bite) resistant to
ciprofloxacin, cefuroxime, clindamycin, erythromycin, rifampin, gentamicin, benzylpenicillin, oxacillin.
4.3.2. Broth Microdilution Assay
This assay was applied to determine the MIC, according to the guidelines of the Clinical and
Laboratory Standards Institute, using Mueller Hinton (MH) Broth. We prepared 2x stocks of peptides
and serially diluted them in sterile PBS instead of Mueller Hinton Broth, so that the treatment of the
bacteria with the peptides was carried out in a medium containing 50% of MH and 50% of PBS, as
described [52]. The overnight cultures of each strain were transferred to fresh MH media and further
incubated to obtain a mid-logarithmic-growth-phase culture of bacteria. The absorbance of each
bacterial suspension was measured at 620 nm, and bacteria were then diluted to approximately 2 ×
105 CFU/mL. Then, 50 µL of the suspensions were mixed with 50 µL of the peptide dilutions in the
wells of a microtiter plate (pre-treated for 1 h at 37 ◦C with 0.2% bovine serum albumin (BSA) in water,
sterilized by filtration, to diminish the non-specific binding of the peptides to the plastic surfaces).
After incubation for 18 h at 37 ◦C, the MIC was read as the lowest concentration of antimicrobial
agent resulting in the complete inhibition of visible growth; results were obtained from 3–5 independent
determinations and are shown as medians.
The overall activity against a set of tested bacterial strains was determined by way of the commonly
used geometric mean of measured MIC values [29,53,54]. Unlike the arithmetic mean, this parameter
is less sensitive to positive outbursts (extreme values) [55], so that possible isolated cases of bacterial
resistance do not dramatically outweigh all other MIC values. At the same time, the geometric mean
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can still discriminate antimicrobial agents showing minor variations in activity; in other words, it has a
better “resolution” than the median MIC (MIC50) [54]. Some mathematical basics for choosing the
geometric mean for antimicrobial activity comparison are further discussed in the Supplementary
Chapter S3.
4.3.3. Membrane Permeabilization Assay
The E. coli ML35p outer membrane permeability was assessed by monitoring hydrolysis
of the chromogenic β-lactamase substrate nitrocefin (3-(2,4-dinitrostyryl)-(6R,7R)-7-(2-thienyl
acetamido)ceph-3-em-4-carboxylic acid) (Calbiochem-Novabiochem, San-Diego, CA, USA) by detection
of the hydrolysis product at 486 nm. Inner membrane permeability was monitored by measuring the
hydrolysis of o-nitrophenyl-β-d-galactoside (ONPG, Sigma, La Jolla, CA, USA) at 420 nm [15]. The
E. coli ML35p strain expresses a plasmid-encoded periplasmic β-lactamase; it constitutively expresses
cytoplasmic β-galactosidase and lacks lactose permease [15]. E. coli ML35p was maintained on
trypticase soy agar plates containing 100 mg of ampicillin per mL. The bacteria used for antimicrobial
testing or membrane permeability assays were picked from a single colony, incubated in 50 mL of
sterile Trypticase soy broth for 16 h at 37 ◦C, washed three times with 10 mM sodium phosphate
buffer (pH 7.4), adjusted to an optical density at 620 nm of 1 (2.5 × 108 CFU/mL), and kept on ice until
use. The assays were performed in 96-well microtiter plates that were monitored every minute with
a SpectraMax 250 Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) using
the SOFTmax PRO software supplied by the manufacturer. The final incubation medium contained
10 mM sodium phosphate buffer, 100 mM NaCl, pH 7.4. Incubation wells (final volume of 100 µL) also
contained either 2.5 mM of ONPG or 20 µM of nitrocefin, 2.5× 107 CFU/mL of washed, stationary-phase
E. coli ML35p cells, and the peptide of interest at a concentration equal to 2×MIC or an equivalent
volume of acidified water (negative controls). Assays were run at 37 ◦C, with 5 s of shaking every
minute. The reactions were started by adding the bacteria. The data were processed using the Sigma
Plot 11 software; the results of a typical experiment are presented at the Figure 5.
4.4. Cytotoxicity Assays
4.4.1. Hemolytic Activity
Hemolysis assays were carried out on human red blood cells according to the ethical principles
of the Declaration of Helsinki. Peripheral blood was drawn from healthy donors (written informed
consent was obtained from all volunteers) into vacutainers containing EDTA under aseptic conditions
and washed twice with an ice-cold phosphate buffered saline (PBS). The supernatant was discarded, and
the pellet was resuspended in PBS. Hemolytic action was tested by incubating increasing concentrations
of peptides with a suspension (2.5% v/v) of washed red blood cells in PBS. After 30 min at 37 ◦C,
the tubes were centrifuged for 3 min at 10,000 g. Hemoglobin release was monitored at 540 nm using
the SpectraMax 250 Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). Total
lysis (100% hemolysis) was determined by adding 1% (v/v) Triton X-100, and the negative control
value was determined by incubating red blood cells in buffer only. The percentage of hemolysis was
calculated as:
% Hemolysis = ((Aexper − Acontrol)/(Atotal − Acontrol)) × 100, (1)
where Aexper and Acontrol signify the absorbance values of the supernatants from treated and untreated
red blood cells, and Atotal is the supernatant of the cells treated with 1% Triton X-100. All evaluations
were repeated in 3–6 separate experiments, carried out in triplicates.
4.4.2. MTT Test
The standard MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test was used
for the examination of the cytotoxic activity of AMPs [56] towards human erithroleukemia cells K-562.
The cells were purchased from Biolot (Saint Petersburg, Russia) and were grown in RPMI 1640 medium
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(Biolot, Saint Petersburg, Russia) supplemented with glutamine and 10% FCS. Before the experiment,
the culturing medium was replaced with serum-free RPMI 1640. Serial dilutions of the peptides in
RPMI were plated in sterile 96-well microplates, and the target cells were dispensed to the microplates
(105 cells/well in RPMI 1640). The plates were incubated for 24 h at 37 ◦C under 5% CO2. Cell-free
media and cells incubated without peptides served as controls. Four hours before the incubation
ended, MTT in PBS (5 mg/mL) was added to each well. After the incubation was stopped by adding
isopropanol/ 0.04 M HCl, the optical density was measured at 540 nm, subtracting the background
absorbance at 690 nm. Toxicity was determined by nonlinear regression analysis of the corresponding
dose–response curves using the Sigma Plot 11 program to calculate the IC50 values (the concentration
of the test substance that reduced the OD540 capacity by 50%).
5. Conclusions
Antibiotic substances from marine invertebrates, and in particular antimicrobial peptides, are a
promising source of novel anti-infective drugs. Among these, arenicin-1 isolated from the lugworm
A. marina coelomocytes, is one of the most potent. It exerts a marked microbicidal activity towards a
variety of Gram-negative and Gram-positive bacteria (including drug-resistant clinical isolates) and
also possesses significant toxicity towards mammalian cells. An intriguing feature of this peptide
is a markedly symmetric arrangement of some residues in its sequence. Several variants have been
elaborated to elucidate the role of this sequence symmetry in the peptides’ function and mode of action,
to determine the effect of structural variations such as backbone cyclization or linearization, and to
probe the importance of key residues for microbicidal efficacy, membranolytic activity, and toxicity
towards mammalian cells.
The results of this work allow us to make the following considerations:
• Stand inversion or palyndromic symmetrization of the arenicin scaffold does not greatly affect
its twisted and kinked antiparallel β-sheet conformation, whereas symmetrization by artificially
branching strands results in a flattened and more regular parallel β-hairpin;
• Inverting the strand residue arrangement of the native peptide causes a decrease in activity.
This may be due to decreased capacity to oligomerize via the inverted N-terminal strand;
• A more symmetric, palindromic strand arrangement did not improve the activity and decreased it
if accompanied by a reduced net charge;
• Increasing symmetry by artificially “branching” strands in a parallel hairpin arrangement allowed
to recover the antimicrobial activity while reducing the cytotoxic activity;
• All variants with a modified symmetry demonstrated a reduced capacity to permeabilize the inner
membrane of E. coli ML35, possibly pointing to a reduced capacity for oligomerization and/or
pore formation.
• The backbone cyclization of the arenicin-1 molecule resulted in improved activity towards
drug-resistant clinical isolates but did not markedly affect cytotoxicity.
• Linearization of the peptide somewhat increased selectivity, while not greatly altering
antimicrobial activity.
These findings suggest that the residue layout of the arenicin-1 molecule plays a significant role
in its biological activity, although the contribution of the peculiar, pseudo-symmetric arrangement
of some residues is still unclear. Furthermore, several other characteristics of the peptides (charge,
hydrophobicity, residues involved in oligomerization) must also be taken in account. We suggest that
recent developments in the computational design of AMPs employing pattern discovery [57] and deep
learning [58], trained also using data from this type of study, may allow for an efficient optimization of
these entangled parameters. Our results indicate that this molecule from a marine animal can serve as
a robust template for the elaboration of novel therapeutic agents and they add to a plethora of other
studies showing that it is arduous to redesign synthetic antimicrobial peptides from natural ones,
improving both efficacy and selectivity.
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